| dc.contributor.author | Sourer, Ayper | |
| dc.contributor.author | Sutcu, Murat | |
| dc.contributor.author | Salman, Nuran | |
| dc.contributor.author | Acar, Manolya | |
| dc.date.accessioned | 2021-03-05T19:30:51Z | |
| dc.date.available | 2021-03-05T19:30:51Z | |
| dc.date.issued | 2017 | |
| dc.identifier.citation | Acar M., Sutcu M., Salman N., Sourer A., "The Risk of Tuberculosis and TNF-alpha Inhibitors", JOURNAL OF PEDIATRIC INFECTION, cilt.11, 2017 | |
| dc.identifier.other | vv_1032021 | |
| dc.identifier.other | av_cfa68f93-c358-489a-9316-8f2c5941aead | |
| dc.identifier.uri | http://hdl.handle.net/20.500.12627/137296 | |
| dc.identifier.uri | https://doi.org/10.5578/ced.201719 | |
| dc.description.abstract | The clinical use of TNF-alpha inhibitors have been increasing in the treatment of autoimmune disorders. The most common anti-TNF-alpha agents on clinical use are ethanercept, infliximab and adalimumab. TNF-alpha is an important mediator in the pathogenesis of tuberculosis, therefore the use of TNFAI increases the risk of tuberculosis. Patients who are on anti-TNF alpha treatment should be carefully evaluated for tuberculosis risk before and during therapy. The recommended screening tools are detailed history, physical examination, tuberculin skin test and/or interferon gamma (IFN-gamma) release assay and chest X-Ray every six months. | |
| dc.language.iso | eng | |
| dc.subject | Sağlık Bilimleri | |
| dc.subject | Çocuk Sağlığı ve Hastalıkları | |
| dc.subject | Dahili Tıp Bilimleri | |
| dc.subject | Tıp | |
| dc.subject | Klinik Tıp (MED) | |
| dc.subject | Klinik Tıp | |
| dc.subject | PEDİATRİ | |
| dc.title | The Risk of Tuberculosis and TNF-alpha Inhibitors | |
| dc.type | Makale | |
| dc.relation.journal | JOURNAL OF PEDIATRIC INFECTION | |
| dc.contributor.department | İstanbul Üniversitesi , , | |
| dc.identifier.volume | 11 | |
| dc.identifier.issue | 2 | |
| dc.contributor.firstauthorID | 243053 | |
